Zacks Investment Research on MSN
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $0.79 per share a year ago.
Historically, data center design was linear: Size the facility to meet demand forecasts and hope for the best. Power and ...
A single intravitreal injection of 4D-150 helped patients with wet age-related macular degeneration maintain visual acuity ...
2don MSN
College football picks: Trend of going for it on 4th down continues to rise and so does success rate
The trend of college football teams going for it on fourth down instead of punting or attempting field goals is continuing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback